Is going for cure in chronic myeloid leukemia possible and justifiable?

Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

Volumn 2012, Issue , 2012, Pages 122-128

  Mahon, François Xavier ^a  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BCR ABL TYROSINE KINASE; BCR-ABL TYROSINE KINASE; BENZAMIDE DERIVATIVE; IMATINIB; PIPERAZINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

CANCER STEM CELL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); CYTOLOGY; DRUG ANTAGONISM; HUMAN; MULTICENTER STUDY (TOPIC); RECURRENT DISEASE; REVIEW; THEORETICAL MODEL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BENZAMIDES; CLINICAL TRIALS AS TOPIC; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MODELS, THEORETICAL; MULTICENTER STUDIES AS TOPIC; NEOPLASTIC STEM CELLS; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RECURRENCE; TREATMENT OUTCOME;

EID: 84879381539     PISSN: None     EISSN: 15204383     Source Type: Journal    
DOI: 10.1182/asheducation.v2012.1.122.3798214     Document Type: Review

References (0)